Human LILRB2/CD85d/ILT4 Alexa Fluor® 488-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2078G
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Gly24-His458
Accession # ACT64556
Specificity
Clonality
Host
Isotype
Applications for Human LILRB2/CD85d/ILT4 Alexa Fluor® 488-conjugated Antibody
Flow Cytometry
Sample: Human peripheral blood monocytes
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: LILRB2/CD85d/ILT4
The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1‑3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5‑9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by downregulation of costimulatory molecules (10, 11). ILT4 mediates tolerogenic DC-induced CD4+ T cell energy in vitro and in vivo (10‑12).
References
- Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7.
- Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317.
- Hunt, J.S. et al. (2005) FASEB J. 19:681.
- Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- Colonna, M. et al. (1998) J. Immunol. 160:3096.
- Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
- Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
- Allen, R.L. et al. (2001) J. Immunol. 167:5543.
- Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
- Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
- Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional LILRB2/CD85d/ILT4 Products
Product Documents for Human LILRB2/CD85d/ILT4 Alexa Fluor® 488-conjugated Antibody
Product Specific Notices for Human LILRB2/CD85d/ILT4 Alexa Fluor® 488-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only